Stock Market & Financial Investment News

News Breaks September 11, 2012 08:02 EDT ARIA ARIAD price target raised to $31 from $23 at BMO Capital BMO Capital predicts that the upcoming EPIC study will move ARIAD's ponatinib towards becoming a treatment for frontline chronic myeloid leukemia. The firm maintains an Outperform rating on the stock. News For ARIA From The Last 14 Days Check below for free stories on ARIA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 08:22 EDT ARIA ARIAD shares should be bought on weakness, says BMO Capital Subscribe for More Information May 16, 2013 07:29 EDT ARIA Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. May 7, 2013 12:02 EDT ARIA ARIAD management to meet with JMP Securities Subscribe for More Information 07:39 EDT ARIA ARIAD reports Q1 EPS (36c), consensus (38c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.